A serological survey of hepatitis B virus (HBV) and hepatitis C virus (HCV) infections was carried out on a random sex- and age-stratified sample of 1006 individuals aged 25-64 years in the Seychelles islands. Anti-HBc and anti-HCV antibodies were detected using commercially available enzyme-linked immunosorbent assays (ELISA), followed by a Western blot assay in the case of a positive result for anti-HCV. The age-adjusted seroprevalence of anti-HBc antibodies was 8.0% (95% CI: 6.5-9.9%) and the percentage prevalence among males/females increased from 7.0/3.1 to 19.1/13.4 in the age groups 25-34 to 55-64 years, respectively. Two men and three women were positive for anti-HCV antibodies, with an age-adjusted seroprevalence of 0.34% (95% CI: 0.1-0.8%). Two out of these five subjects who were positive for anti-HCV also had anti-HBc antibodies. The seroprevalence of anti-HBc was significantly higher in unskilled workers, persons with low education, and heavy drinkers. The age-specific seroprevalence of anti-HBc in this population-based survey, which was conducted in 1994, was approximately three times lower than in a previous patient-based survey carried out in 1979. Although there are methodological differences between the two surveys, it is likely that the substantial decrease in anti-HBc prevalence during the last 15 years may be due to significant socioeconomic development and the systematic screening of blood donors since 1981. Because hepatitis C virus infections are serious and the cost of treatment is high, the fact that the prevalence of anti-HCV antibodies is at present low should not be an argument for not screening blood donors for anti-HCV and eliminating those who are positive.
PIP: This study examined the prevalence of anti-hepatitis Bc virus (HBc) and anti-hepatitis C virus (HCV) antibodies in a random sex- and age-stratified sample of 1006 individuals aged 25-64 years in the Seychelles. The anti-HBc and anti-HCV antibodies were detected using an enzyme-linked immunosorbent assay, followed by a Western blot assay in the case of a positive result for anti-HCV antibodies. Findings revealed that the age-adjusted prevalence of anti-HBc antibodies was 10.4% and 5.8%, respectively, among men and women aged 25-63 years. The presence of anti-HBc antibodies was associated significantly with employment, educational level, and alcohol intake, marginally with economic status, and not at all with ethnic origin. 2 men and 3 women were positive for anti-HCV antibodies, with an age-adjusted seroprevalence of 0.34%. 2 out of these 5 subjects who were positive for anti-HCV antibodies were also positive for anti-HBc antibodies. The age-specific seroprevalence of anti-HBc antibodies in this population study conducted in 1994 was approximately 3 times lower than in a previous patient-based survey carried out in 1979. Although there were methodological differences between the two surveys, it is likely that the substantial decrease in the anti-HBc antibody prevalence during the last 15 years may be due to significant socioeconomic development and the systematic screening of blood donors since 1981.